192705-78-5Relevant academic research and scientific papers
Structure-activity relationships for a novel series of pyrido[2,3- d]pyrimidine tyrosine kinase inhibitors
Hamby, James M.,Connolly, Cleo J. C.,Schroeder, Mel C.,Winters, R. Thomas,Showalter, H. D. Hollis,Panek, Robert L.,Major, Terry C.,Olsewski, Bronislawa,Ryan, Michael J.,Dahring, Tawny,Lu, Gina H.,Keiser, Joan,Amar, Aneesa,Shen, Cindy,Kraker, Alan J.,Slintak, Veronika,Nelson, James M.,Fry, David W.,Bradford, Laura,Hallak, Hussein,Doherty, Annette M.
, p. 2296 - 2303 (2007/10/03)
Screening of a compound library for inhibitors of the fibroblast growth factor (FGFr) and platelet-derived growth factor (PDGFr) receptor tyrosine kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The initial lead, 1-[2- amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea (4b, PD-089828), was found to be a broadly active tyrosine kinase inhibitor. Compound 4b inhibited the PDGFr, FGFr, EGFr, and c-src tyrosine kinases with IC50 values of 1.11, 0.13, 0.45, and 0.22 μM, respectively. Subsequent SAR studies led to the synthesis of new analogs with improved potency, solubility, and bioavailability relative to the initial lead. For example, the introduction of a [4-(diethylamino)butyl]amino side chain into the 2- position of 4b afforded compound 6c with enhanced potency and bioavafiability. Compound 6c inhibited PDGF-stimulated vascular smooth muscle cell proliferation with an IC50 of 0.3 μM. Furthermore, replacement of the 6-(2,6-dichlorophenyl) moiety of 4b with a 6-(3',5'-dimethoxyphenyl) functionality produced a highly selective FGFr tyrosine kinase inhibitor 4e. Compound 4e inhibited the FGFr tyrosine kinase with an IC50 of 0.060 μM, whereas IC50s for the inhibiton of the PDGFr, FGFr, EGFr, c-src, and InsR tyrosine kinases for this compound (4e) were all greater than 50 μM.
Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
Connolly, Cleo J. C.,Hamby, James M.,Schroeder, Mel C.,Barvian, Mark,Lu, Gina H.,Panek, Robert L.,Amar, Aneesa,Shen, Cindy,Kraker, Alan J.,Fry, David W.,Klohs, Wayne D.,Doherty, Annette M.
, p. 2415 - 2420 (2007/10/03)
The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.' In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported.
